Drug intelligence / Profile preview

JI-MT

Development stage: Preclinical
Modality: Small Molecules
Administration: Jejunal

Overview

JI-MT is a novel indomethacin derivative that has demonstrated inhibitory activity against Platelet-Derived Growth Factor Receptor-alpha (PDGFR-α). It has shown cytotoxic effects in HepG2 cell lines and potential for the treatment of hepatocellular carcinoma (HCC) in in-vivo studies. Its mechanism of action involves inhibiting PDGFR-α, which is implicated in tumor growth and progression.

Targets

PDGFRA (Platelet-derived growth factor receptor alpha)

Beyond the preview

Go deeper on JI-MT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JI-MT.

Explore the full profile